Swiss Rockets secured an exclusive license from MGI Tech and Complete Genomics for CoolMPS sequencing chemistry outside Asia‑Pacific, positioning the Basel‑based incubator to enter next‑generation sequencing instrument markets. The company plans to launch a CoolMPS‑based sequencer as early as next year by partnering on R&D and manufacturing. Swiss Rockets framed the move as leveraging a Swiss base to commercialize CoolMPS in Europe and the U.S., citing geopolitical advantages and market access. The deal could intensify competition for NGS instrumentation and provide an alternative chemistry platform to Illumina and others.